{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-035666","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2026-07-31T21:00:19+00:00","discovered_at":"2026-07-31T21:02:00.288044+00:00","generated_at":"2026-07-31T21:02:33.332502+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Calidi Biotherapeutics effects 1-for-16 reverse stock split to maintain NYSE American listing","bullets":["Reverse stock split at 1-for-16 ratio effective July 30, 2026; trading begins July 31 under symbol CLDI.","Post-split shares outstanding: ~2.45M Common Stock and 9,375 Non-Voting Common Stock.","Split approved by stockholders on June 12, 2026; no fractional shares issued.","New CUSIP number 320703 507 assigned to Common Stock.","Purpose: increase per-share price and support continued listing on NYSE American."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-035666","json":"https://secwatch.observer/filing/0001493152-26-035666.json","markdown":"https://secwatch.observer/filing/0001493152-26-035666.md","text":"https://secwatch.observer/filing/0001493152-26-035666.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226035666/0001493152-26-035666-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226035666/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-31T21:02:33.332502+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}